PERFUSE study – UEG week 2019 Barcelona

Mis à jour : 29 oct. 2019

Biogen – pioneer in neuroscience and in the commercialization of biosimilars is one of Sanoïa’s prestigious clients and presented new real-world data on anti-TNF biosimilars FLIXABI™ and IMRALDI™ at the United European Gastroenterology (UEG) Week in Barcelona, October 19-23.

Presented data comprise an interim analysis of PERFUSE –operated by Sanoïa in a full service mode– , a non-interventional, stage 4 clinical study(1), investigating the persistence and immunogenicity of FLIXABI™ in three subsets of inflammatory bowel disease (IBD) patients receiving FLIXABI™.

(1) Bouhnik Y., Fautrel B., Desjeux G., Freudensprung U., Addison J. and Brigui A. PERFUSE: a French Prospective/Retrospective Non-Interventional Cohort Study of Infliximab Naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; 1st Interim Analysis. United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019, 626-627.


e-Health Services SAS


  • LinkedIn Social Icône


(French Clinical Research Association)

Sanoïa is an agile Contract Research Organization for tailor-made Real-Life studies.